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Abstract  
 
The receptors CD96 and TIGIT are expressed on the surface of T and NK cells and recent studies 
suggest both play important inhibitory roles in immune function. CD96 -/-has been shown to 
modulate immune cell activity in mice, with Cd96 mice displaying hypersensitive NK cell responses to 
immune challenge and significant tumor resistance. TIGIT overexpression has been shown to reduce 
NK cell-mediated cytotoxicity. TIGIT is also upregulated on T-cells during cancer and chronic viral 
infection, with expression associated with effector T-cell exhaustion and increased Treg suppression. 
The counterbalance between the putative inhibitory CD96, TIGIT receptors and the activating 
receptor, CD226, offers unique strategies for immuno-oncology drug development. Blocking CD96 or 
TIGIT with monoclonal antibodies (mAbs) has been shown to improve tumor control in mice, in 
particular when used in combination with PD-1/PD-L1 blockade. These results have highlighted these 
pathways as promising new targets for immune modulation. This review will examine the rationale 
behind targeting CD96 and TIGIT and discuss the potential approaches in translating these preclinical 
findings into novel clinical agents.       
 
 
 
Background  
 
CD155, CD226 and TIGIT in immune regulation and cancer  
The development of antibodies targeting immune checkpoint receptors PD-1 (1) and CTLA-4 (2) has 
been a monumental step forward in the clinical success of cancer immunotherapy. While highly 
successful as monotherapies, more than a dozen alternate pathways exist that modulate immune 
responses (3), suggesting combination approaches may greatly augment response rates. This 
hypothesis is supported by a recent clinical trial, demonstrating improved objective responses when 
PD-1 and CTLA-4 inhibitors were used in combination (4). While antibodies against CTLA-4 and PD-1 
are thought to act predominately through T-cells, another immune cell type the natural killer (NK) 
cell is gaining traction as a target for cancer immunotherapy, particularly for the control of 
metastases and blood cancers (5). NK cells are part of the innate lymphocyte family and play a 
critical role in viral and tumor immune surveillance. NK cells act by detecting and killing infected or 
cancerous cells via perforin-mediated cytotoxicity and also regulate immune responses through the 
release of cytokines (6).   
 
Candidate pathways for cancer immunotherapy include a cluster of immunoglobulin superfamily 
receptors that interact with nectin and nectin-like molecules (NECL), which are critical regulators in 
immune surveillance. Nectin and NECL family members were first characterized as adhesion 
molecules, mediating both homo- and heterophilic interactions (7). A diverse range of nectin and 
NECL proteins-receptor interactions exist, with roles in immune regulation, virus entry to cells and 
normal development (7, 8). Several nectin and NECL proteins have prominent roles in cancer 
surveillance, with CD155 (necl-5, PVR) the most well-characterized. While expression is low in 
normal tissue, CD155 is highly expressed on many cancer cell lines and primary tumors (9). CD155 
has been linked with enhanced tumor proliferation (10) and migration (9). CD155 is also upregulated 
on many immune cells during inflammation (11) and on tumor-associated APCs (12). CD155 
expression is thought to modulate T and NK cell responses through CD226, TIGIT and CD96 
interactions (Table 1 and Figure 1).   
 
Engagement between CD155 and CD226 or TIGIT has been a major focus of research, with CD226 
having dual roles as both an activating and adhesion receptor on NK cells (13, 14), while TIGIT acts as 
an inhibitory receptor, shown to reduce NK cell cytokine production and cytotoxicity (15, 16). CD226 
is also considered an +activating receptor for CD8 T-cells (17) with its downregulation observed in 
advanced cancer and associated with T-cell exhaustion (12, 18). The role of CD226 in -/-tumor 
immune surveillance is supported by accelerated tumor growth in Cd226 +mice (19, 20). Conversely, 
TIGIT is highly upregulated on both CD8 T-cells and Tregs in many clinical tumor settings (12, 18, 21), 
with expression also correlating with other immune checkpoints such as PD-1. Across in vitro human 
assays, primate models and mouse tumor models, TIGIT blockade has been shown to enhance T-cell 
function in particular, in combination with other checkpoints such as PD-1(12), PD-L1 (21, 22) and 
TIM-3 (23). While CD155 is considered the dominant ligand for CD226 and TIGIT, CD226 can also 
interact with CD112 (24) and TIGIT can interact with CD112 and CD113 (25).    
 
CD96 expression, ligand interactions and putative signaling pathways  
CD96 (TACTILE) was first identified as an Ig superfamily receptor (26), however it is now known to be 
a member of the extended nectin/necl family and its role in immune function has received little 
attention until recently. CD96 expression is broadly similar between mice and humans, and is 
preseŶt oŶ a proportioŶ of heŵatopoietiĐ steŵ Đells, αβ aŶd ɶɷ T-cells, NK cells and a sub-
population of B-cells in humans (27-ϯϭͿ aŶd preseŶt oŶ αβ aŶd ɶɷ T-cells, NK cells and NKT cells in 
mice (11, 32). CD96 is not expressed on other immune cells and expression is generally low or absent 
in organs without lymphocyte infiltrate (29). Of interest, CD96 is expressed at far higher levels in 
mice, with almost all cells positive for the receptor at resting state while basal expression is lower in 
humans (26). Interestingly, CD96 has been shown to be highly expressed in acute myeloid leukemia 
(AML), T-cell acute lymphoblastic leukemia (T-ALL) (29) and myelodysplastic syndromes (33). CD96 
has additionally been proposed as a cancer stem cell marker in leukaemia (30, 33).  
 
Akin to DNAM and TIGIT, the main ligand for CD96 is CD155, to which it binds with an affinity 
stronger than CD226, but weaker than TIGIT. Human CD96, CD226, TIGIT bind to CD155 with 
dissociation constants (Kd) of 37.6 nM, 119 nM and 3.15 nM respectively (25). Of note, mouse CD96 
(mCD96) but not human CD96 (hCD96) has been shown to bind CD111 (nectin-1) (32). Other key 
differences also exist between human and mice. For example, hCD96 exists as two splice variants 
that confer different binding affinities to CD155 (29). The sequence of hCD96 but not mCD96 
contains a potential SH-2 domain binding-site within the cytoplasmic tail in the form of an YXXM 
motif (29), similar to that found in activating receptors. Both human and mouse CD96 sequences 
contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (34) that putatively may provide 
inhibitory signals to lymphocytes following ligation. However, downstream signaling of the CD96 
receptor has not been evaluated in detail. Given CD155 contains cytoplasmic signaling motifs, it will 
be of interest to determine whether CD96 engagement triggers reverse CD155 signaling. Indeed, 
TIGIT/CD155 ligation has been shown to modulate the function of CD155 expressing DC cells, 
inducing IL-10 secretion (25).     
  
Functions of CD96   
Initial investigations of CD96 biology suggested a role in mediating human NK cell adhesion to CD155 
expressing target cells and was also proposed as a weak NK cell activating receptor (31). CD96 was 
also described as an adhesion molecule to CD155 and CD111 in mouse studies (29, 32). The first 
evidence that CD96 might be acting as -/-an inhibitory receptor was shown in Cd96 mice, where NK 
cells produced greater IFN-ɶ iŶ respoŶses to LP“, IL-12 or IL-18 stimulation (11). This study also -/-
demonstrated a role for CD96 in cancer immune surveillance, with Cd96 mice showing robust 
resistance to experimental lung metastases and MCA-induced fibrosarcomas. The potential of 
targeting CD96 to enhance NK cell control of metastases was highlighted in our recent article (35). In 
this study, we demonstrated that mAbs against CD96 could reduce the number of lung metastases in 
a range of spontaneous and experimental models. The activity of anti-CD96 was dependent on NK 
cells, IFN-ɶ aŶd CDϮϮϲ.    
 
Clinical-Translational Advances  
 
Therapeutic approaches  
The complexity of interaction dynamics within the CD96/TIGIT/CD226/CD155 axis poses both 
opportunities and challenges for therapeutic translation in oncology. At the most fundamental level, 
the net inhibitory signals from either TIGIT or CD96 are counterbalanced via multiple mechanisms by 
the activating signal of CD226. Thus, an understanding of the dynamic regulation of CD226 
expression and activity must be a core consideration when attempting to modulate TIGIT and CD96 
activity. Therapeutic antibodies that reduce co-inhibitory signaling via blockade of CD155 binding to 
CD96 and/or TIGIT have considerable experimental support in preclinical cancer models (21, 35). 
These data support a correlation between antibody blockade of the CD96/TIGIT/CD155 axis with 
enhanced anti-cancer activity through increased +CD8 T-cell or increased NK cell function for anti-
TIGIT and anti-CD96, respectively. As an alternative to blockade of ligand binding to co-inhibitory 
receptors, antibodies that stabilize CD155 binding to CD226 might selectively potentiate an 
activating signal, and may serve as a therapeutic strategy by providing a more robust counterbalance 
to TIGIT and CD96.  
 
Functional TIGIT suppression of anti-tumor responses is both intrinsic to effector T-cells and indirect, 
via enhancement of Treg activity. The enrichment of TIGIT expression on tumor-infiltrating Tregs 
compared to peripheral Tregs (23) would suggest that maximal anti-tumor response could be 
achieved via modification of the mAb Fc region. Increased binding to activating FcR could mediate a 
selective +depletion of TIGIT Tregs at the tumor site through antibody dependent cellular-
cytotoxicity (ADCC) or -phagocytosis (ADCP), similar to what has been described for anti-CTLA-4 
antibodies (36). The relatively greater TIGIT expression on Tregs versus T-effector cells within tumor 
site would optimally enable this approach. While +CD96 is expressed on CD4 T-cells (11), further 
work is necessary to determine whether CD96 influences the suppressive function of Tregs, and to 
define CD96 expression on Tregs and Teff within the tumor microenvironment and periphery. 
Importantly, the ability of blocking CD96 mAb to reduce B16F10 lung metastases was not dependent 
on activating FcR (35), indicating that anti-tumor activity was not due to selective immune subset 
depletion.    
 
Since receptor-binding domains are conserved in CD155 (25), therapeutic antibodies targeting this 
ligand are not likely to have selective effects on inhibitory (TIGIT and CD96) signals versus activating 
(CD226) pathways. However, the relatively higher binding affinity of CD155 to TIGIT or CD96 
compared with the lower affinity CD226 interaction can theoretically be exploited for drug 
development. Greater selectivity towards CD226-dependent signaling and subsequent lymphocyte 
aĐtiǀatioŶ Đould ďe aĐhieǀed usiŶg eŶgiŶeered ǀariaŶts ;or ͞ŵuteiŶs͟Ϳ of CDϭϱϱ or other Ŷectins that 
retain TIGIT and/or CD96 binding but cannot bind CD226. By competing with native CD155, these 
modalities would functionally block TIGIT and/or CD96 inhibitory signaling but retain the activation 
through CD226. The ability of TIGIT to form a signaling-competent homodimer (37) or, conversely, a 
heterocomplex with CD226 which impairs CD226 activation signaling (21), reveals the dynamic  
interactions of this receptor system and other potential anti-cancer drug approaches. Antibodies 
that target the interface between TIGIT homodimers may reduce inhibitory signaling, while targeting 
interactions between TIGIT and CD226 extracellular domains might conceivably block heterocomplex 
formation and relieve TIGIT-mediated inhibition of CD226 signaling.   
 
Preclinical mechanistic data and known lymphocyte expression patterns suggests that combination 
immunotherapy strategies targeting TIGIT and/or CD96 will have improved anti-tumor responses. 
For instance, combining anti-CD96 with either anti-CTLA-4 or anti-PD-1 mAbs resulted in a greater 
reduction in B16F10 lung metastasis compared to monotherapy treatment, an effect dependent on 
NK cells (35). Moreover, survival of mice with 4T1.2 spontaneous metastases, was significantly 
increased by combining anti-CD96 and anti-CTLA-4 or anti-PD-1 compared to monotherapy. 
Similarly, treatment of CT26 tumors with a combination of anti-TIGIT and anti-PD-L1 dramatically 
improved anti-tumor responses compared to each as a monotherapy -/-(21), while using an anti-
TIM-3 mAb in Tigit mice improved the control of B16F10 metastases and subcutaneous tumors (23). 
There is also evidence that targeting TIGIT -/- and CD96 in combination could be exploited as a 
therapeutic strategy. While Tigit mice showed enhanced immunity to either B16F10 melanoma 
grown as subcutaneous -/-tumors (23), experimental B16F10 lung metastasis were not reduced in 
Tigit mice -/-(11). However treatment of Tigit mice with an anti-CD96 mAb resulted in a greater 
reduction of B16F10 or EO771 lung metastasis than that observed upon anti-CD96 mAb treatment in 
wild-type mice (35), suggesting that these pathways may instruct non-overlapping lymphocyte 
subsets and/or distinct molecular mechanisms.   
 
While immunotherapy functions by increasing host anti-tumor immunity, the induction of immune-
related adverse events (irAEs) in patients can limit certain approaches. Clinically, CTLA-4 blockade is 
associated with more high-grade irAEs -/-than PD-1 (4), and in agreement, Ctla-4 mice develop a 
lethal lymphoproliferative -/-disorder (38). However,  Pd-1 mice, can spontaneously develop a range 
of less -/- -/-severe immune pathologies (39, 40). To date, Tigit (41) or Cd96 mice (11) have -/- 
not shown spontaneous development of overt immune pathologies, however Tigit mice were more 
sensitive to the induction of experimental autoimmune encephalomyelitis (41) and TIGIT blockade 
was shown to increase experimental arthritis development (42). While caution in the over 
interpretation of animal studies is advised, these preclinical observations suggest CD96 or TIGIT 
blocking therapies may have favourable clinical toxicity profiles.  
 
Open questions and challenges  
Currently, the foremost challenge for translating TIGIT- or CD96-targeted therapies is to functionally 
validate blockade of these receptors in human lymphocytes. Two useful validation surrogates 
include the analysis of TIGIT and CD96 expression/function in patient tumor infiltrating lymphocytes 
(TILs), or on T-cells from chronic virus-infected individuals, and any correlation with exhaustion 
markers +and/or phenotype. TIGIT was reportedly co-expressed with PD-1 on effector CD8 T-cells 
during HIV or SIV infection and increased TIGIT expression correlated with + +disease progression 
(22). TIGIT levels were elevated on CD4 and CD8 TILs and co-+expressed with PD-1 on CD8 T-cells in 
NSCLC, colon cancer and melanoma samples (12, 21), with similar expression seen on PBMCs from 
AML patients (18). +  Promisingly, treatment of HIV-specific CD8 T-cells with an anti-TIGIT mAb 
iŶĐreased IFNɶ produĐtioŶ (22). Similarly, treatment of tumor-specific melanoma +CD8 TILs with 
anti-TIGIT mAb augmented proliferation and IFN-ɶ produĐtioŶ ;ϭϮ, ϰϯͿ. These data are ĐoŶsisteŶt 
with a co-inhibitory function for TIGIT in the context of chronic antigen stimulation in humans and 
provide a sound rationale for further development of TIGIT blockade therapeutics.   
 
Currently, the validation of hCD96 as a potential immunotherapy target is not as advanced as TIGIT. 
While CD96 surface expression is increased on human T-cells 11  +post activation (26, 44), a high 
percentage of resting CD8 T-cells from healthy + +controls express CD96 and the fraction of CD96 
CD8 T-cells was reduced in HIV-infected individuals (44). Interestingly, serum levels of soluble CD96 
were found to be elevated in patients with chronic viral hepatitis B infection (45), suggesting that 
persistent antigen exposure can increase CD96 levels and/or cell surface shedding. In human 
cancers, CD96 surface expression on TILs versus PBMCs has not been well characterized, however 
CD96 mRNA expression, along with TIGIT, was highly expressed and associated with a T-cell 
signature in lung cancer (21). Current data from preclinical cancer models indicates an inhibitory 
function for CD96 on NK cells, but whether the same function exists on mouse T-cells and human NK 
or T-cells remains to be elucidated. The determination of CD96 expression in human T-cell subsets, 
TILs and a comprehensive validation of functional pathway activity in human immune cells is an area 
of active research and are obligatory prerequisites for the development of CD96 blockade 
therapeutics.  
 
Presently, the relationship between specific structural/biophysical attributes and optimal anti-cancer 
mechanisms of TIGIT- or CD96-targeted therapies are not well +described. The rationale for blocking 
CD155/TIGIT binding to augment CD8 T-cell function as a cancer immunotherapy approach is sound. 
While TIGIT robustly inhibits human NK cell-mediated cytotoxicity in vitro (16, 46), in mice, TIGIT NK 
cell-mediated tumor suppression is less pronounced than CD96 (11). Moreover, the high potentially 
dominant contribution of TIGIT Treg cells in the anti-cancer immune response (23) suggests that a 
blocking antibody might also augment effector functions. These observations should be reconciled 
to understand the full, integrated 12 + +contribution of TIGIT on distinct lymphocytes (eg CD8 T-cells, 
CD4 T-cells and NK cells) for an optimal anti-tumor response.   
 
The ability of CD96 or TIGIT to counterbalance activation mediated by CD226 appears to drive most 
of the anti-cancer activities of CD96/TIGIT targeted therapies. Indeed, a CD226 blocking antibody 
reversed suppression of CT26 tumors by an anti-TIGIT mAb (21). Similarly, CD96 suppression of 
B16F10 lung metastases, via genetic deletion or blocking antibody was mostly dependent on intact 
CD226 function (11, 35). Within this paired inhibitory/activating axis, the magnitude and integrated 
quality (activation versus inhibition) of lymphocyte signaling is dictated by the relative availability 
(and selective competitive binding) of certain ligands but also by the kinetics and coordinated 
expression of receptor levels. To this end, CD226 was +down regulated on CD8 T-cells and NK cells in 
AML patients (18, 47), and low +CD226 was detected on CD8 TILs from melanoma patients 
compared with PBMCs (12). CD226, TIGIT and CD96 receptor expression was reportedly dynamically 
modulated by ligand exposure. CD155 interaction decreases surface expression of CD226 (48) and 
CD96 (31) on contacting cells. Conversely, increased levels of -/-CD226 and CD96 have been 
observed in Cd155 mice, while TIGIT levels were unchanged (49). These dynamic alterations in 
activating and inhibitory receptor levels may tip the balance in net signaling output in a context-
dependent manner and potentially alter responses to CD96- and TIGIT- targeted therapies.   
 
Clearly, emerging preclinical evidence suggests there is much promise in modulating the 
CD96/TIGIT/DNAM/CD155 axis for immuno-oncology. A clearer understanding of the molecular- and 
context-dependent mechanisms by which CD96 and TIGIT 13 function in immunity will pave the way 
for its therapeutic application in cancer, either as monotherapies or in combination with other 
therapies. At this stage, the ultimate impact of fine-tuning the function of TIGIT and CD96 receptors 
on cancer patient outcomes are wholly unknown but will be interesting to monitor as knowledge 
advances.      
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Table 1.  Biological roles of TIGIT and CD96 in lymphocyte function and outcomes of pathway 
inhibition relevant to immunotherapy 
 
 
 
 
 
 
Figure 1. The regulation of inhibitory versus activation signals in NK cell and T-cells by 
CD96/TIGIT/CD226 receptors is achieved by complex receptor/ligand and receptor/receptor 
counterbalancing mechanisms. CD155 and CD96, TIGIT, CD226 are all members of the Ig superfamily 
and all share similar variable or constant Ig motifs in the extracellular domains, single-pass 
transmembrane regions and short cytoplasmic domains.   
 
A). CD155 levels on different cells are upregulated as a result of cellular stress. In cancer, CD155 is 
increased on transformed cells and antigen presenting cells (APC) within the tumor 
microenvironment and is sensed by the CD96/TIGIT/CD226 receptors to modulate anti-tumor 
immunity.   
 
B). Upon exposure to increasing levels of CD155, the net activation or inhibition of lymphocytes is 
fine-tuned by the integrated signalling of CD96, TIGIT and CD226. This net integration is dictated by 
the relative binding affinity of CD155 for different receptors, relative abundance of activation 
(CD226) vs. inhibitory (CD96, TIGIT) receptors, the strength and quality of signal transduction by 
each receptor and the modulation of ligand binding and biochemical signal transduction by homo- 
and heterodimerization of receptor complexes.  The cytoplasmic domain of CD226 has a tyrosine 
(Y322) and serine (S329), which become phosphorylated in a CD155-dependent manner.   
Phosphorylation of Y322 confers binding of CD226 to the SH2-domain containing protein Grb2 and 
downstream signalling. Serine 329 phosphorylation of CD226 mediates activation of protein kinase C 
and the association with lymphocyte function-associated antigen 1 (LFA1) as an intermediate for 
further signal transduction.  TIGIT contains an immunoreceptor tyrosine inhibitory motif (ITIM) 
domain and an immunoglobulin tail tyrosine (ITT) motif within the cytoplasmic tail.  Upon ligand 
binding, both the ITT and ITIM domains of TIGIT are phosphorylated and recruit adaptor and 
signaling molecules.  While both mCD96 and hCD96 contain an ITIM-like domain, the human CD96 
cytoplasmic domain uniquely also includes a YXXM motif.  A detailed review of CD226, TIGIT and 
CD96 signaling mechanisms is described in (8).  
 
C). These molecular regulatory mechanisms provide distinct opportunities for drug development in 
immuno-oncology.  1). Therapeutic antibodies that block CD155 binding to CD96 or TIGIT would 
reverse the inhibitory signaling by these receptors. Using either anti-CD96 or anti-TIGIT mAbs, this 
approach has received specific experimental support in mouse cancer models. 2). Antibody or 
ŵutated ligaŶd ;͞ŵuteiŶ͟Ϳ ŵodalities ǁhiĐh alloǁ prefereŶtial sigŶaliŶg through the aĐtivating 
receptor CD226 might tip the balance between CD155-dependent activation and inhibition.  For 
instance, a mAb that recognizes and stabilizes the unique interaction complex of CD155/CD226 
could enhance stimulatory signaling through CD226. Alternatively, engineered mutations in CD155 
muteins that preferentially bind CD96 and/or TIGIT might competitively inhibit native CD155 binding 
and enhance lymphocyte activation. 3). The blockade of TIGIT/CD226 heterodimer or TIGIT/TIGIT 
homodimer by drug modalities would potentially reduce TIGIT-dependent inhibitory signals.    
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